Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 9, 2000

View Archived Issues

Update on worldwide phase III trials of Maxamine

PDL highlights product pipeline at New York City healthcare conference

Forbes Medi-Tech's FM-VP4 inhibits cholesterol absorption in preclinical trials

Corixa outlines significant Q3 developments

Boston Life Sciences' O-1369 shows promise for PD

Questcor receives continued funding for program in neuroprotection

Abgenix acquires ImmGenics

Connetics' foam formulation for scalp dermatoses launched in U.S.

Human antibody agreement signed by Medarex and Lilly

Dyax and Bracco form diagnostic imaging alliance

Company Profile: Achillion

First phase III trial of HspE7 commences in anal dysplasia

Toxicity and pharmacokinetics of new camptothecin analogue CKD-602 determined in phase I trial

NCI-EORTC-AACR news: dual topoisomerase I/II inhibitors promising as solid tumor therapy

Clinical pharmacokinetics and toxicity of NX-211 characterized at major cancer meeting

Novel neuroprotective aminoindan undergoes extensive preclinical testing at Teva

First potent and selective, nonpeptide thrombin receptor antagonists described by Schering-Plough

Synthesis and use of new NK1 antagonists reported by AstraZeneca

PC-PLD inhibitors preferentially abrogate growth and proliferation of tumor cell lines

Novel compounds interacting with metabotropic glutamate receptors discovered at Roche

Antibacterial agents in the British Biotech pipeline

Sanofi-Synthelabo presents new therapeutics for CNS and GI disorders

Recently issued international patent covers Sanofi-Synthelabo's new NK1 ligands

French lab discloses new series with high affinity for D3 receptors

Modulators of chemokine CCR receptors claimed in patent literature by AstraZeneca

Potential new treatments for bone and cartilage disorders revealed by SB scientists

Pfizer patents fructose-lowering sorbitol dehydrogenase inhibitors

New class of tubulin polymerization inhibitors presented in Amsterdam

Addition of oprelvekin allows completion of full-dose therapy for hepatitis C

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 16, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 16, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
Hits’ Hyperlab launches as ‘virtual AI lab’ for new drug discovery
BioWorld Science
Things once done in laboratories can now be done with computers and AI, said Kim Woo-youn, CEO and cofounder of Hits Inc. “We live in the age of ‘digital...
ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug
BioWorld
ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...